The University of Chicago Header Logo

Stuart M. Sprague

TitleClinical Professor
InstitutionUniversity of Chicago
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sprague SM, Reddy G, Jermasek D, Gupta P, Sprague SM, Reddy G, Jermasek D, Gupta P. High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders. Am J Nephrol. 2023; 54(5-6):219-223. PMID: 37231835.
      Citations:    Fields:    Translation:Humans
    2. Pao AC, Shahzad SR, Song S, Ganesan C, Conti S, Leppert J, Cheung AK, Ix JH, Isakova T, Wolf M, Raj DS, Sprague SM, Fried LF, Gassman J, Fong P, Koike S, Raphael KL. Response to Alkali Administration in Women and Men With and Without CKD. Kidney Med. 2023 Jul; 5(7):100670. PMID: 37492113; PMCID: PMC10363557.
    3. Prasad PV, Li LP, Hack B, Leloudas N, Sprague SM. Quantitative Blood Oxygenation Level Dependent Magnetic Resonance Imaging for Estimating Intra-renal Oxygen Availability Demonstrates Kidneys Are Hypoxemic in Human CKD. Kidney Int Rep. 2023 May; 8(5):1057-1067. PMID: 37180507; PMCID: PMC10166744.
      Citations: 2     
    4. Dream S, Kuo LE, Kuo JH, Sprague SM, Nwariaku FE, Wolf M, Olson JA, Moe SM, Lindeman B, Chen H. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism. Ann Surg. 2022 09 01; 276(3):e141-e176. PMID: 35848728.
      Citations: 5     Fields:    Translation:Humans
    5. Li LP, Leidner AS, Wilt E, Mikheev A, Rusinek H, Sprague SM, Kohn OF, Srivastava A, Prasad PV. Radiomics-Based Image Phenotyping of Kidney Apparent Diffusion Coefficient Maps: Preliminary Feasibility & Efficacy. J Clin Med. 2022 Apr 01; 11(7). PMID: 35407587; PMCID: PMC8999417.
      Citations: 3     
    6. Coyne DW, Sprague SM, Vervloet M, Ramos R, Kalantar-Zadeh K. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022 04; 35(3):875-888. PMID: 35138627; PMCID: PMC8995279.
      Citations: 1     Fields:    Translation:Humans
    7. Wang AA, Cai X, Srivastava A, Prasad PV, Sprague SM, Carr J, Wolf M, Ix JH, Block GA, Chonchol M, Raphael KL, Cheung AK, Raj DS, Gassman JJ, Rahsepar AA, Middleton JP, Fried LF, Sarnari R, Isakova T, Mehta R. Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360. 2022 02 24; 3(2):258-268. PMID: 35373122; PMCID: PMC8967624.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    8. Sprague SM, Ketteler M. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472. PMID: 34511018.
      Citations:    Fields:    Translation:Humans
    9. Yee J, Rosenbaum D, Jacobs JW, Sprague SM. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications. Am J Nephrol. 2021; 52(7):522-530. PMID: 34515051.
      Citations: 2     Fields:    Translation:HumansAnimals
    10. Sprague SM, Warady BA. Family Genetic Screening to Identify Cases of Alport Syndrome: A Case Study Report. Kidney Med. 2021 Sep-Oct; 3(5):866-867. PMID: 34693267; PMCID: PMC8515063.
    11. Sprague SM, Martin KJ, Coyne DW. Phosphate Balance and CKD-Mineral Bone Disease. Kidney Int Rep. 2021 Aug; 6(8):2049-2058. PMID: 34386654; PMCID: PMC8343779.
      Citations: 11     
    12. Li LP, Thacker JM, Li W, Hack B, Wang C, Kohn O, Sprague SM, Prasad PV. Medullary Blood Oxygen Level-Dependent MRI Index (R2*) is Associated with Annual Loss of Kidney Function in Moderate CKD. Am J Nephrol. 2020; 51(12):966-974. PMID: 33508835; PMCID: PMC7954090.
      Citations: 5     Fields:    Translation:Humans
    13. Sprague SM. The Enigma of Vascular Calcifications. Kidney Int Rep. 2020 Dec; 5(12):2127-2129. PMID: 33306042; PMCID: PMC7710879.
    14. Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439. PMID: 32585670; PMCID: PMC7592954.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    15. Funk F, Ketteler M, Rastogi A, Walpen S, Covic AC, Sprague SM, Floege J. Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. Nephrol Dial Transplant. 2020 06 01; 35(6):946-954. PMID: 32259248; PMCID: PMC7282824.
      Citations: 1     Fields:    Translation:Animals
    16. Hyder R, Sprague SM. Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1041-1043. PMID: 32461217; PMCID: PMC7341786.
      Citations: 2     Fields:    Translation:Humans
    17. Cai X, Lee J, Li W, Larive B, Kendrick C, Gassman JJ, Middleton JP, Carr J, Raphael KL, Cheung AK, Raj DS, Chonchol MB, Fried LF, Block GA, Sprague SM, Wolf M, Ix JH, Prasad PV, Isakova T, Srivastava A. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin J Am Soc Nephrol. 2020 06 08; 15(6):776-783. PMID: 32345747; PMCID: PMC7274274.
      Citations: 11     Fields:    Translation:Humans
    18. Coyne DW, Ficociello LH, Parameswaran V, Rosen MM, Mullon C, Kossmann RJ, Sprague SM. Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. Kidney Med. 2020 May-Jun; 2(3):307-316. PMID: 32734250; PMCID: PMC7380402.
      Citations: 4     
    19. Sprague SM. Interventions for Preventing Bone Disease Following Kidney Transplantation: Is There Evidence for Specific Therapy? Am J Kidney Dis. 2020 05; 75(5):809-811. PMID: 32192784.
      Citations:    Fields:    Translation:Humans
    20. Raphael KL, Isakova T, Ix JH, Raj DS, Wolf M, Fried LF, Gassman JJ, Kendrick C, Larive B, Flessner MF, Mendley SR, Hostetter TH, Block GA, Li P, Middleton JP, Sprague SM, Wesson DE, Cheung AK. A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. J Am Soc Nephrol. 2020 01; 31(1):161-174. PMID: 31848294; PMCID: PMC6934992.
      Citations: 16     Fields:    Translation:Humans
    21. Li LP, Milani B, Pruijm M, Kohn O, Sprague S, Hack B, Prasad P. Renal BOLD MRI in patients with chronic kidney disease: comparison of the semi-automated twelve layer concentric objects (TLCO) and manual ROI methods. MAGMA. 2020 Feb; 33(1):113-120. PMID: 31823276.
      Citations: 3     Fields:    Translation:Humans
    22. Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170. PMID: 29846719; PMCID: PMC6603395.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    23. Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 10; 96(4):1030-1036. PMID: 31377056.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    24. Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol. 2019 06; 30(6):1096-1108. PMID: 31085679; PMCID: PMC6551774.
      Citations: 43     Fields:    Translation:Humans
    25. Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293. PMID: 30878999.
      Citations: 24     Fields:    Translation:Humans
    26. Prasad PV, Li LP, Thacker JM, Li W, Hack B, Kohn O, Sprague SM. Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease. Am J Nephrol. 2019; 49(2):114-124. PMID: 30669143; PMCID: PMC6387452.
      Citations: 21     Fields:    Translation:Humans
    27. Altman AM, Sprague SM. Mineral and Bone Disease in Kidney Transplant Recipients. Curr Osteoporos Rep. 2018 12; 16(6):703-711. PMID: 30390201.
      Citations: 6     Fields:    Translation:Humans
    28. Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. J Diabetes Complications. 2018 Dec; 32(12):1113-1117. PMID: 30318163.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    29. Sprague SM, Floege J. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148. PMID: 29985725.
      Citations: 3     Fields:    Translation:Humans
    30. Prasad PV, Li W, Raj DS, Carr J, Carr M, Thacker J, Li LP, Wang C, Sprague SM, Ix JH, Chonchol M, Block G, Cheung AK, Raphael K, Gassman J, Wolf M, Fried LF, Isakova T, CKD Optimal Management with BInders and NicotinamidE (COMBINE) study group. Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD. Kidney Int Rep. 2018 Nov; 3(6):1467-1472. PMID: 30450473; PMCID: PMC6224659.
      Citations: 8     
    31. Dhillon-Jhattu S, Sprague SM. Should phosphate management be limited to the KDIGO/ KDOQI guidelines? Semin Dial. 2018 07; 31(4):377-381. PMID: 29671909.
      Citations: 2     Fields:    Translation:Humans
    32. Sprague SM, Ketteler M, Covic AC, Rakov V, Walpen S, Rastogi A, Floege J. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 10; 22(4):480-491. PMID: 29656600.
      Citations: 5     Fields:    Translation:Humans
    33. Li LP, Thacker J, Li W, Tan H, Wang C, Kohn O, Sprague S, Prasad P. Consistency of Multiple Renal Functional MRI Measurements Over 18 Months. J Magn Reson Imaging. 2018 08; 48(2):514-521. PMID: 29517835; PMCID: PMC6105537.
      Citations: 2     Fields:    Translation:Humans
    34. Sprague S, Bhandari M, Heetveld MJ, Liew S, Scott T, Bzovsky S, Heels-Ansdell D, Zhou Q, Swiontkowski M, Schemitsch EH, FAITH Investigators. Factors associated with health-related quality of life, hip function, and health utility after operative management of femoral neck fractures. Bone Joint J. 2018 03 01; 100-B(3):361-369. PMID: 29589490.
      Citations: 14     Fields:    Translation:Humans
    35. Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM, Floege J. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1918-1926. PMID: 28339993.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    36. Covic AC, Ketteler M, Sprague SM, Lisk L, Rakov V, Rastogi A, Floege J. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017 Aug 01; 32(8):1330-1338. PMID: 27342579; PMCID: PMC5837623.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    37. Coyne DW, Ficociello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, Mullon C, Maddux FW, Kossmann RJ, Sprague SM. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67. PMID: 28587714; PMCID: PMC5514614.
      Citations: 14     Fields:    Translation:Humans
    38. Sprague SM, Strugnell SA, Bishop CW. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Rev Endocrinol Metab. 2017 09; 12(5):289-301. PMID: 30058895.
      Citations: 8     Fields:    
    39. Alexander AJ, Jahangir D, Lazarus M, Sprague SM. Imaging in Chronic Kidney Disease-Metabolic Bone Disease. Semin Dial. 2017 07; 30(4):361-368. PMID: 28382631.
      Citations: 6     Fields:    Translation:Humans
    40. Santiago L, Menaa C, Arias M, Martin P, Metkar S, Erill N, Gonzalez-Rumayor V, Esser E, Raja S, Simon MM, Sprague SM, Gabay C, Martinez-Lostao L, Froelich CJ, Jaime-Sánchez P, Comas L, Galvez EM, Pardo J. Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis. Arthritis Rheumatol. 2017 Feb; 69(2):320-334. PMID: 27598995.
      Citations: 18     Fields:    Translation:Animals
    41. Sturgeon CM, Sprague S, Almond A, Cavalier E, Fraser WD, Algeciras-Schimnich A, Singh R, Souberbielle JC, Vesper HW, IFCC Working Group for PTH. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH. Clin Chim Acta. 2017 Apr; 467:42-47. PMID: 27746210; PMCID: PMC5695551.
      Citations: 10     Fields:    Translation:Humans
    42. Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, Lee S, Petkovich PM, Bishop CW. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325. PMID: 27676085.
      Citations: 26     Fields:    Translation:Humans
    43. Li LP, Tan H, Thacker JM, Li W, Zhou Y, Kohn O, Sprague SM, Prasad PV. Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging. Kidney Int Rep. 2017 Jan; 2(1):36-43. PMID: 28868513; PMCID: PMC5575771.
      Citations: 25     
    44. Sprague SM, Covic AC, Ketteler M, Botha J, Chong EM, Rastogi A, Floege J. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12. PMID: 27434393.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    45. Nigwekar SU, Sprague SM. We Do Too Many Parathyroidectomies for Calciphylaxis. Semin Dial. 2016 07; 29(4):312-4. PMID: 27082830.
      Citations: 9     Fields:    Translation:Humans
    46. Li LP, Li W, Zhou Y, Sprague SM, Prasad PV, Thacker JM. Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging: A Sensitive and Objective Analysis. Invest Radiol. 2015 Dec; 50(12):821-7. PMID: 26193455; PMCID: PMC4765917.
      Citations: 15     Fields:    Translation:Humans
    47. Prasad PV, Thacker J, Li LP, Haque M, Li W, Koenigs H, Zhou Y, Sprague SM. Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study. PLoS One. 2015; 10(10):e0139661. PMID: 26430736; PMCID: PMC4591972.
      Citations: 32     Fields:    Translation:Humans
    48. Sprague SM, Bellorin-Font E, Malluche HH, D'Haese PC, Du H, Manley T, Rojas E, Moe SM, Jorgetti V, Carvalho AB, Ferreira A, Drüeke TB. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66. PMID: 26321176.
      Citations: 100     Fields:    Translation:Humans
    49. Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. J Am Soc Nephrol. 2015 Oct; 26(10):2328-39. PMID: 25967123; PMCID: PMC4587706.
      Citations: 59     Fields:    Translation:Humans
    50. Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40. PMID: 25904755; PMCID: PMC4455208.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    51. Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30. PMID: 25873267; PMCID: PMC4455198.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    52. Worcester EM, Coe FL, Sprague SM, Ennis JL. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70. PMID: 25736620.
      Citations: 14     Fields:    Translation:Humans
    53. Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study Group, Floege J. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Jun; 30(6):1037-46. PMID: 25691681; PMCID: PMC4438742.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    54. Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45. PMID: 25572630.
      Citations: 17     Fields:    Translation:Humans
    55. Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 05; 9(9):1620-6. PMID: 24970869; PMCID: PMC4152818.
      Citations: 22     Fields:    Translation:Humans
    56. Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, PA21 Study Group, Floege J. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep; 86(3):638-47. PMID: 24646861; PMCID: PMC4150998.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    57. Zhang Y, Lapidos KA, Gal-Moscovici A, Sprague SM, Ameer GA. A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease. Artif Organs. 2014 Jun; 38(6):474-83. PMID: 24206165; PMCID: PMC4016998.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    58. Sprague SM. Painful skin ulcers in a hemodialysis patient. Clin J Am Soc Nephrol. 2014 Jan; 9(1):166-73. PMID: 24202137; PMCID: PMC3878687.
      Citations: 12     Fields:    Translation:Humans
    59. Ho LT, Sprague SM. Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis. 2013 Sep; 20(5):423-6. PMID: 23978548.
      Citations: 4     Fields:    Translation:Humans
    60. Sprague SM, Moe SM. Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013 Feb; 8(2):321. PMID: 23160258.
      Citations: 4     Fields:    Translation:Humans
    61. Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013 Feb; 61(2):310-25. PMID: 23102732.
      Citations: 23     Fields:    Translation:Humans
    62. Sprague SM, Moe SM. The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol. 2013 Feb; 8(2):313-8. PMID: 23037984; PMCID: PMC3562858.
      Citations: 12     Fields:    Translation:Humans
    63. Lapidos KA, Sprague SM, Ameer GA. Impact of serum source and inflammatory cytokines on the isolation of endothelial colony-forming cells from peripheral blood. J Tissue Eng Regen Med. 2014 Sep; 8(9):747-56. PMID: 22888041.
      Citations: 4     Fields:    Translation:HumansCells
    64. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant. 2011 Nov; 26(11):3440-5. PMID: 22039013; PMCID: PMC3203632.
      Citations: 14     Fields:    Translation:Humans
    65. Sprague SM. Impact of CKD on coronary artery calcifications. Am J Kidney Dis. 2011 Oct; 58(4):503-5. PMID: 21944960.
      Citations:    Fields:    Translation:Humans
    66. Edwards BJ, Desai A, Tsai J, Du H, Edwards GR, Bunta AD, Hahr A, Abecassis M, Sprague S. Elevated incidence of fractures in solid-organ transplant recipients on glucocorticoid-sparing immunosuppressive regimens. J Osteoporos. 2011; 2011:591793. PMID: 21922049; PMCID: PMC3172972.
      Citations: 9     
    67. Sprague SM. Is bone mineral density measurement of any value in a dialysis patient? Semin Dial. 2011 Jul-Aug; 24(4):433-4. PMID: 21801230.
      Citations:    Fields:    Translation:Humans
    68. Sprague SM. Renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2010 Dec; 17(6):535-9. PMID: 21030840.
      Citations: 5     Fields:    Translation:Humans
    69. Chung EJ, Qiu H, Kodali P, Yang S, Sprague SM, Hwong J, Koh J, Ameer GA. Early tissue response to citric acid-based micro- and nanocomposites. J Biomed Mater Res A. 2011 Jan; 96(1):29-37. PMID: 20949482; PMCID: PMC2991399.
      Citations: 6     Fields:    Translation:HumansAnimals
    70. Copley JB, Germain M, Stern L, Pankewycz O, Katznelson S, Shah T, Wang O, Turner SA, Sprague SM. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010 Sep; 42(7):2503-8. PMID: 20832532.
      Citations: 4     Fields:    Translation:Humans
    71. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int. 2010 Jul; 78(2):146-51. PMID: 20505658.
      Citations: 20     Fields:    Translation:Humans
    72. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May; 55(5):773-99. PMID: 20363541.
      Citations: 84     Fields:    Translation:Humans
    73. Park JC, Kovesdy CP, Duong U, Streja E, Rambod M, Nissenson AR, Sprague SM, Kalantar-Zadeh K. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92. PMID: 20345388; PMCID: PMC5509753.
      Citations: 30     Fields:    Translation:Humans
    74. Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, Kopple JD, Kalantar-Zadeh K. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54. PMID: 20199875; PMCID: PMC3175364.
      Citations: 34     Fields:    Translation:Humans
    75. Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8. PMID: 20133492.
      Citations: 13     Fields:    Translation:Humans
    76. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8. PMID: 19825330.
      Citations: 18     Fields:    Translation:Humans
    77. Sprague SM, Evenepoel P, Curzi MP, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G, González MT. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76. PMID: 19696213; PMCID: PMC2736698.
      Citations: 9     Fields:    Translation:Humans
    78. Barnato S, Sprague SM. Advances in renal bone disease: osteoporosis and chronic kidney disease. Curr Rheumatol Rep. 2009 Jul; 11(3):185-90. PMID: 19604462.
      Citations: 4     Fields:    Translation:Humans
    79. Khosla N, Sprague SM. When is Vitamin D contraindicated in dialysis patients? Semin Dial. 2009 May-Jun; 22(3):249-51. PMID: 19573002.
      Citations:    Fields:    Translation:Humans
    80. Huang M, Sprague SM. Bone disease in kidney transplant patients. Semin Nephrol. 2009 Mar; 29(2):166-73. PMID: 19371807.
      Citations: 1     Fields:    Translation:Humans
    81. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85. PMID: 19056618; PMCID: PMC2615694.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    82. Gal-Moscovici A, Sprague SM. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov; 3 Suppl 3:S170-4. PMID: 18988703; PMCID: PMC3152284.
      Citations: 3     Fields:    Translation:Humans
    83. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Fosrenol Overview Research Evaluation Study for Early Experience Study Group. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45. PMID: 18579668; PMCID: PMC2518797.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    84. Menaa C, Esser E, Sprague SM. Beta2-microglobulin stimulates osteoclast formation. Kidney Int. 2008 Jun; 73(11):1275-81. PMID: 18368032.
      Citations: 21     Fields:    Translation:AnimalsCells
    85. Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb; 14(1):18-27. PMID: 18238737.
      Citations: 17     Fields:    Translation:Humans
    86. Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res. 2007 Dec; 22 Suppl 2:V91-4. PMID: 18290730.
      Citations: 11     Fields:    Translation:Humans
    87. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007 Dec; 23(12):3167-75. PMID: 17991307.
      Citations: 27     Fields:    Translation:Humans
    88. Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K. Abnormal bone and mineral metabolism in kidney transplant patients--a review. Am J Nephrol. 2008; 28(2):246-53. PMID: 17989497.
      Citations: 17     Fields:    Translation:Humans
    89. Guo M, Cox B, Mahale S, Davis W, Carranza A, Hayes K, Sprague S, Jimenez D, Ding Y. Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates blood-brain barrier dysfunction in stroke. Neuroscience. 2008 Jan 24; 151(2):340-51. PMID: 18160227.
      Citations: 40     Fields:    Translation:Animals
    90. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106. PMID: 17914251.
      Citations: 21     Fields:    Translation:Humans
    91. Sprague SM. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2007 Oct; 72(7):895; author reply 895-6. PMID: 17882244.
      Citations: 1     Fields:    Translation:Humans
    92. Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Semin Dial. 2007 Sep-Oct; 20(5):423-30. PMID: 17897249.
      Citations: 25     Fields:    Translation:Humans
    93. Schumock GT, Sprague SM. Clinical and economic burden of fractures in patients with renal osteodystrophy. Clin Nephrol. 2007 Apr; 67(4):201-8. PMID: 17474555.
      Citations: 6     Fields:    Translation:Humans
    94. Sprague SM. Renal function and risk of hip and vertebral fractures in older women: is it always osteoporosis? Arch Intern Med. 2007 Jan 22; 167(2):115-6. PMID: 17242310.
      Citations: 3     Fields:    Translation:Humans
    95. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43. PMID: 17215573.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    96. Gal-Moscovici A, Sprague SM. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis. 2007 Jan; 14(1):27-36. PMID: 17200041.
      Citations: 14     Fields:    Translation:Humans
    97. Gal-Moscovici A, Sprague SM, Hutchison AJ, Shah N, Piraino B, Cunningham J. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed? Semin Dial. 2007 Jan-Feb; 20(1):24-32. PMID: 17244115.
      Citations:    Fields:    Translation:Humans
    98. Gal-Moscovici A, Sprague SM. Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. Clin Drug Investig. 2007; 27(2):105-13. PMID: 17217315.
      Citations:    Fields:    Translation:Humans
    99. Moe S, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO), Drüeke T. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Jun; 69(11):1945-53. PMID: 16641930.
      Citations: 618     Fields:    Translation:Humans
    100. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006 Feb; 47(2):263-76. PMID: 16431255.
      Citations: 58     Fields:    Translation:Humans
    101. Zisman AL, Sprague SM. Bone disease after kidney transplantation. Adv Chronic Kidney Dis. 2006 Jan; 13(1):35-46. PMID: 16412969.
      Citations: 4     Fields:    Translation:Humans
    102. Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005 Nov-Dec; 25(6):591-5. PMID: 16282676.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    103. Moe SM, Cunningham J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM, Bommer J. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93. PMID: 16030053.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    104. Daniels CM, Woolverton EM, Sprague SM, Ameer GA. Assessment of the stability of an immunoadsorbent for the extracorporeal removal of Beta-2-microglobulin from blood. Blood Purif. 2005; 23(4):287-97. PMID: 15942167.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    105. Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004 Oct 27; 78(8):1233-6. PMID: 15502727.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    106. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90. PMID: 15112179.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    107. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004 May; 19(5):1174-81. PMID: 15004264.
      Citations: 23     Fields:    Translation:Humans
    108. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J, Osteoporosis Work Group. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004 Mar; 43(3):566-71. PMID: 14981616.
      Citations: 50     Fields:    Translation:Humans
    109. Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin Nephrol. 2004 Jan; 24(1):82-90. PMID: 14730514.
      Citations: 8     Fields:    Translation:Humans
    110. Dzido G, Sprague SM. Dialysis-related amyloidosis. Minerva Urol Nefrol. 2003 Jun; 55(2):121-9. PMID: 12847416.
      Citations: 4     Fields:    Translation:HumansCells
    111. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr; 63(4):1483-90. PMID: 12631365.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    112. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54. PMID: 12472790.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    113. Ho LT, Sprague SM, Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol. 2002 Nov; 22(6):488-93. PMID: 12430093.
      Citations: 8     Fields:    Translation:Humans
    114. Moberly JB, Mujais S, Gehr T, Hamburger R, Sprague S, Kucharski A, Reynolds R, Ogrinc F, Martis L, Wolfson M. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl. 2002 Oct; (81):S23-33. PMID: 12230479.
      Citations: 25     Fields:    Translation:HumansCells
    115. Sprague SM, Ho LT. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol. 2002 Aug; 58(2):155-60. PMID: 12227689.
      Citations: 1     Fields:    Translation:Humans
    116. Kim G, Sprague SM, Kim G, Sprague SM. Use of vitamin D analogs in chronic renal failure. Adv Ren Replace Ther. 2002 Jul; 9(3):175-83. PMID: 12203199.
      Citations: 1     Fields:    Translation:Humans
    117. Ho LT, Sprague SM. Percutaneous bone biopsy in the diagnosis of renal osteodystrophy. Semin Nephrol. 2002 May; 22(3):268-75. PMID: 12012312.
      Citations: 1     Fields:    Translation:Humans
    118. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D, Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001 Nov; 38(5 Suppl 5):S51-6. PMID: 11689388.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    119. Dhingra RK, Sprague SM, Ojo AO, Leavey SF. Posttransplant bone disease: a case illustrating dramatic improvements in bone density with vitamin D replacement therapy. Transplantation. 2001 Jun 27; 71(12):1856-9. PMID: 11455270.
      Citations: 1     Fields:    Translation:Humans
    120. Balint E, Sprague SM, Balint E, Sprague SM. Beta(2)-microglobulin and bone cell metabolism. Nephrol Dial Transplant. 2001 Jun; 16(6):1108-11. PMID: 11390706.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    121. Tran M, Rutecki GW, Sprague SM. The pathogenesis of beta(2)-microglobulin-induced bone lesions in dialysis-related amyloidosis. Semin Dial. 2001 Mar-Apr; 14(2):131-3. PMID: 11264782.
      Citations: 1     Fields:    Translation:HumansAnimals
    122. Balint E, Szabo P, Marshall CF, Sprague SM. Glucose-induced inhibition of in vitro bone mineralization. Bone. 2001 Jan; 28(1):21-8. PMID: 11165939.
      Citations: 63     Fields:    Translation:AnimalsCells
    123. Balint E, Marshall CF, Sprague SM. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis. 2000 Oct; 36(4):789-96. PMID: 11007682.
      Citations: 7     Fields:    Translation:Animals
    124. Sprague SM. Mechanism of transplantation-associated bone loss. Pediatr Nephrol. 2000 Jul; 14(7):650-3. PMID: 10912536.
      Citations: 3     Fields:    Translation:HumansAnimals
    125. Weiger TM, Holmqvist MH, Levitan IB, Clark FT, Sprague S, Huang WJ, Ge P, Wang C, Lawson D, Jurman ME, Glucksmann MA, Silos-Santiago I, DiStefano PS, Curtis R. A novel nervous system beta subunit that downregulates human large conductance calcium-dependent potassium channels. J Neurosci. 2000 May 15; 20(10):3563-70. PMID: 10804197; PMCID: PMC6772688.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    126. Sprague SM. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial. 2000 May-Jun; 13(3):152-5. PMID: 10833774.
      Citations: 6     Fields:    Translation:Humans
    127. Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A, Martin-Malo A, Rodriguez M, Almaden Y, Felsenfeld AJ. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35. PMID: 10804023.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    128. Balint E, Marshall CF, Sprague SM. Role of interleukin-6 in beta2-microglobulin-induced bone mineral dissolution. Kidney Int. 2000 Apr; 57(4):1599-607. PMID: 10760095.
      Citations: 3     Fields:    Translation:AnimalsCells
    129. Dranitzki-Elhalel M, Wald H, Popovtzer MM, Sprague SM. 1,25-Dihydroxyvitamin D3-induced calcium efflux from calvaria is mediated by protein kinase C. J Bone Miner Res. 1999 Nov; 14(11):1822-7. PMID: 10571681.
      Citations:    Fields:    Translation:AnimalsCells
    130. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, Langman CB, Salinger MH, Sprague SM. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999 Mar; 14(3):456-63. PMID: 10027911.
      Citations: 38     Fields:    Translation:Humans
    131. Whang K, Healy KE, Elenz DR, Nam EK, Tsai DC, Thomas CH, Nuber GW, Glorieux FH, Travers R, Sprague SM. Engineering bone regeneration with bioabsorbable scaffolds with novel microarchitecture. Tissue Eng. 1999 Feb; 5(1):35-51. PMID: 10207188.
      Citations: 64     Fields:    Translation:Animals
    132. Whang K, Tsai DC, Nam EK, Aitken M, Sprague SM, Patel PK, Healy KE. Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mater Res. 1998 Dec 15; 42(4):491-9. PMID: 9827671.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    133. Chiu MY, Sprague SM, Bruce DS, Woodle ES, Thistlethwaite JR, Josephson MA. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol. 1998 Apr; 9(4):677-83. PMID: 9555671.
      Citations: 15     Fields:    Translation:Humans
    134. Sprague SM, Popovtzer MM, Dranitzki-Elhalel M, Wald H. Parathyroid hormone-induced calcium efflux from cultured bone is mediated by protein kinase C translocation. Am J Physiol. 1996 Dec; 271(6 Pt 2):F1139-46. PMID: 8997387.
      Citations: 1     Fields:    Translation:AnimalsCells
    135. Miyata T, Sprague SM. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Nephrol Dial Transplant. 1996; 11 Suppl 3:86-90. PMID: 8840320.
      Citations: 2     Fields:    Translation:Humans
    136. Miyata T, Kawai R, Taketomi S, Sprague SM. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial Transplant. 1996; 11 Suppl 5:54-7. PMID: 9044308.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    137. Bushinsky DA, Sprague SM, Hallegot P, Girod C, Chabala JM, Levi-Setti R. Effects of aluminum on bone surface ion composition. J Bone Miner Res. 1995 Dec; 10(12):1988-97. PMID: 8619380.
      Citations: 7     Fields:    Translation:Animals
    138. Moe SM, Hack BK, Cummings SA, Sprague SM. Role of IL-1 beta and prostaglandins in beta 2-microglobulin-induced bone mineral dissolution. Kidney Int. 1995 Feb; 47(2):587-91. PMID: 7723245.
      Citations: 2     Fields:    Translation:Animals
    139. Sprague SM, Popovtzer MM. Is beta 2-microglobulin a mediator of bone disease? Kidney Int. 1995 Jan; 47(1):1-6. PMID: 7731134.
      Citations: 1     Fields:    Translation:HumansAnimals
    140. Bartosh SM, Sprague SM, Nakagawa Y, Baron BW, Aronson AJ. Severe hypercalcemia following neonatal liver transplantation. Miner Electrolyte Metab. 1995; 21(6):428-30. PMID: 8592488.
      Citations:    Fields:    Translation:Humans
    141. Moe SM, Sprague SM. Uremic encephalopathy. Clin Nephrol. 1994 Oct; 42(4):251-6. PMID: 7834918.
      Citations: 5     Fields:    Translation:Humans
    142. Sprague SM, Krieger NS, Bushinsky DA. Greater inhibition of in vitro bone mineralization with metabolic than respiratory acidosis. Kidney Int. 1994 Oct; 46(4):1199-206. PMID: 7861717.
      Citations: 9     Fields:    Translation:AnimalsCells
    143. Hammes M, DeMory A, Sprague SM. Hypocalcemia in end-stage renal disease: a consequence of spontaneous parathyroid gland infarction. Am J Kidney Dis. 1994 Sep; 24(3):519-22. PMID: 8079980.
      Citations:    Fields:    Translation:Humans
    144. Moe SM, Yu BO, Sprague SM. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7. PMID: 8352257.
      Citations: 3     Fields:    Translation:Humans
    145. Sprague SM, Krieger NS, Bushinsky DA. Aluminum inhibits bone nodule formation and calcification in vitro. Am J Physiol. 1993 May; 264(5 Pt 2):F882-90. PMID: 8498542.
      Citations: 4     Fields:    Translation:AnimalsCells
    146. Moe SM, Sprague SM. Beta 2-microglobulin induces calcium efflux from cultured neonatal mouse calvariae. Am J Physiol. 1992 Sep; 263(3 Pt 2):F540-5. PMID: 1415583.
      Citations: 7     Fields:    Translation:AnimalsCells
    147. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9. PMID: 1595701.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    148. Spiegel DM, Sprague SM. Serum amyloid P component: a predictor of clinical beta 2-microglobulin amyloidosis. Am J Kidney Dis. 1992 May; 19(5):427-32. PMID: 1585929.
      Citations: 3     Fields:    Translation:Humans
    149. Murray JC, Tanner CM, Sprague SM. Aluminum neurotoxicity: a reevaluation. Clin Neuropharmacol. 1991 Apr; 14(2):179-85. PMID: 2015614.
      Citations: 1     Fields:    Translation:Humans
    150. Sprague SM, Bushinsky DA. Mechanism of aluminum-induced calcium efflux from cultured neonatal mouse calvariae. Am J Physiol. 1990 Mar; 258(3 Pt 2):F583-8. PMID: 2316667.
      Citations:    Fields:    Translation:Animals
    151. Corwin HL, Sprague SM, DeLaria GA, Norusis MJ. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg. 1989 Dec; 98(6):1107-12. PMID: 2586128.
      Citations: 17     Fields:    Translation:Humans
    152. Sprague SM, Corwin HL, Tanner CM, Wilson RS, Green BJ, Goetz CG. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72. PMID: 3178374.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    153. Warren GV, Sprague SM, Corwin HL. Sarcoidosis presenting as acute renal failure during pregnancy. Am J Kidney Dis. 1988 Aug; 12(2):161-3. PMID: 3400635.
      Citations:    Fields:    Translation:Humans
    154. Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986 Oct; 146(10):2063-4. PMID: 3767553.
      Citations:    Fields:    Translation:Humans
    155. Shore D, Sprague SM, Mayor GH, Moreno EC, Apostoles PS, Wyatt RJ. Aluminum-fluoride complexes: preclinical studies. J Environ Pathol Toxicol Oncol. 1985 Sep-Oct; 6(1):9-13. PMID: 4067838.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    156. Commissaris RL, Cordon JJ, Sprague S, Keiser J, Mayor GH, Rech RH. Behavioral changes in rats after chronic aluminum and parathyroid hormone administration. Neurobehav Toxicol Teratol. 1982 May-Jun; 4(3):403-10. PMID: 7099360.
      Citations: 7     Fields:    Translation:Animals
    157. Mayor GH, Sprague SM, Sanchez TV. Determinants of tissue aluminum concentration. Am J Kidney Dis. 1981 Nov; 1(3):141-5. PMID: 7036718.
      Citations: 1     Fields:    Translation:HumansAnimals
    158. Mayor GH, Sprague SM, Hourani MR, Sanchez TV. Parathyroid hormone-mediated aluminum deposition and egress in the rat. Kidney Int. 1980 Jan; 17(1):40-4. PMID: 7374019.
      Citations: 11     Fields:    Translation:Animals
    159. McCormack KM, Ottosen LD, Sanger VL, Sprague S, Mayor GH, Hook JB. Effect of prenatal administration of aluminum and parathyroid hormone on fetal development in the rat. Proc Soc Exp Biol Med. 1979 May; 161(1):74-7. PMID: 441074.
      Citations: 3     Fields:    Translation:Animals
    160. Mayor GH, Keiser JA, Sanchez TV, Sprague SM, Hook JB. Factors affecting tissue aluminum concentration. J Dial. 1978; 2(5-6):471-81. PMID: 374433.
      Citations:    Fields:    Translation:HumansAnimals
    Sprague's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (484)
    Co-Authors (12)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors